Debiopharm Forges AI-powered Alliance With NetTargets to Pioneer Dual-payload ADCs Against Drug-resistant Cancers

Contributed by: Business Wire

Logo

Tags

Technology

Research

Health Technology

Biotechnology

Health

Pharmaceutical

Science

Artificial Intelligence

Oncology

NetTargets

More Like This

Debiopharm and Genome & Company Reach Agreement for Potential First-In Class Oncology Antibody Drug Conjugate Family

Debiopharm to Reveal Insights From Their ADC, DDR Inhibitor, and Antibody Conjugation Technology Research at the 2025 AACR Conference in Chicago

Debiopharm to Unveil New Pre-Clinical and Clinical Research Advances in DDR Inhibition, Dual Payload ADCs, and AI-Driven Biomarkers at AACR 2026

Debiopharm Extends SunRock Biopharma Partnership for Antibody Drug Conjugates Targeting HER3 in EGFR Mutated Cancers

TNL’s AI Digital Cells Lab platform and Debiopharm’s deep pharmaceutical expertise may bring cancer drugs into new frontiers of innovation (Graphic: Business Wire)

Debiopharm and ThinkingNodeLife.ai Forge a Strategic Partnership to Propel Cancer Drug Development with AI Digital Cell Clones

Debiopharm & WhiteLab Genomics Announce a Strategic Partnership to Advance Drug Target and Design in Oncology

Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 2026

Debiopharm and Oncodesign Services Launch Strategic Collaboration to Propel Radiopharmaceuticals in Preclinical Research